In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Genzyme v. Atrium

This article was originally published in The Gray Sheet

  • News

Executive Summary

Cambridge, Massachusetts-based Genzyme Corp. and Genzyme Surgical Products file patent suit against Atrium Medical in Delaware district court Nov. 14 alleging Atrium's Express and Oasis chest drainage devices infringe certain patents, including those related to dry suction and/or dry seal technology. The patents relate to Genzyme's Pleur-Evac line of chest drainage systems. Genzyme seeks to prevent the continued manufacture of Express and Oasis until the patents expire, and will seek undetermined monetary awards

Table

View full table

Tags:
Latest Headlines

Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics

Fujifilm Demonstrates Health Specialism With European HealthTech Spinout

Financing Quarterly Statistics, Q1 2024

Helping Organizations Deliver On KPIs And Giving Staff A Voice

See All
UsernamePublicRestriction

Register

MT014141

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By